Although pre- and post-treatment tissues were not required nor analyzed for these patients during the dose-escalation portion, the ongoing phase II trial includes tumor tissue analysis of the tumor immune microenvironment, microbiome from stool samples, and circulating immune biomarkers both pre- and post-therapy for the combination of CIMAvax-EGF and immune checkpoint inhibitors. This evidence concerns the gene EGF and neoplasm.